The role of possibly high carcinogenic risk human papilloma virus the development of cervical malignant pathology: systematic review and meta-analysis


DOI: https://dx.doi.org/10.18565/epidem.2023.13.4.106-14

Vinogradova N.A., Domonova E.A., Vinokurov M.A., Popova A.A.

Central Research Institute of Epidemiology of Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia
Objective. Evaluation of the prevalence of possibly high carcinogenic risk (possibly HCR) human papillomavirus (HPV) and its contribution to the development of malignant cervical neoplasms with an assessment of the reliability of the data obtained depending on the diagnostic approaches used.
Materials and methods. The search in the MEDLINE (PubMed), CyberLeninka, and eLibrary databases (search depth – 21 years) was performed. In total, more than 400 articles in Russian, English, and German were analyzed. Statistical analyses of results and data visualization were performed in the R environment.
Results. It was found that the proportion of possibly HCR HPV from all HPV-positive results among conditionally healthy women (n = 20,989) was 14% (95% CI 9–20), in the group with a cytological conclusion LSIL and ASCUS (n = 2785) – 20% (95% CI 13–29). Among patients with a cytological conclusion HSIL and «cervical cancer» (n = 6316), the frequency of detection of possibly HCR HPV 26, 53, 66, 67 68, 70, 73, 82 types was a total of 6% (95% CI 3–16). When different diagnostic approaches are used simultaneously to exclude false-negative results, the number of HPV-negative cases of cervical cancer was 1% (95% CI 0–2). The comparable level of type-specific transforming activity of HCR and possibly HCR HPV indicates that possibly HCR HPV may be the only prognostic factor for the development of cervical cancer.
Conclusion. The data obtained indicate the need to recommend the inclusion of HPV of possibly HCR in epidemiological monitoring and screening programs for malignant cervical pathology.
Keywords: human papillomavirus of possibly high carcinogenic risk, HPV-associated cervical cancer, human papillomavirus, meta-analysis, systematic review
Read entire article

Literature

1. Schiffman M., Doorbar J., Wentzensen N., de Sanjosé S., Fakhry C., Monk B.J. et al. Carcinogenic human papillomavirus infection. Nat. Rev. Dis. Primers. 2016; 2(1): 16086. DOI:10.1038/nrdp.2016.86


2. Demarco M., Hyun N., Carter-Pokras O., Raine-Bennett T.R., Cheung L., Chen X. et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. Clinical Medicine 2020; 22: 100293. DOI:10.1016/j.eclinm.2020.100293


3. Reich O., Regauer S., Kashofer K. Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests – A European prospective single center study Gynecologic. Oncology 2020; 158(1), 112–16. DOI: 10.1016/j.ygyno.2020.04.685


4. Cervical cancer screening. IARC Handbooks of Cancer Prevention. Volume 18. 2022; 1–456. https://publications.iarc.fr/604


5. Biological agents. IARC Monogr Eval Carcinog Risks Hum. IARC 2012; 100B: 1–475. https://publications.iarc.fr/119 PMID:23189750


6. Thomas A., Necchi A., Muneer A., Tobias-Machado M., Tran A.T.H., Rompuy A.-S.V. et al. Penile cancer. Nat. Rev. Dis. Primers 2021; 7(1). DOI: 10.1038/s41572-021-00246-5


7. Yamashina T., Shimatani M., Takeo M., Sasaki K., Orino M., Saito N. et al. Viral Infection in Esophageal, Gastric, and Colorectal Cancer. Healthcare (Basel). 2022; 10(9): 1626. DOI: 10.3390/healthcare10091626


8. Combes J.-D., Guan P., Franceschi S., Clifford G.M. Judging the carcinogenicity of rare human papillomavirus types. Int. J. Cancer 2015; 136(3): 740–2. doi:10.1002/ ijc.29019 PMID:24917192


9. Arbyn M., de Sanjose S., Saraiya M., Sideri M., Palefsky J., Lacey C. et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int. J. Cancer 2012; 131: 1969–82. DOI: 10.1002/ijc.27650


10. Гаджиева К.А. Частота встречаемости генотипов вируса папилломы человека онкогенного риска по результатам ретроспективного и проспективного анализов по г. Баку. Международный научно-исследовательский журнал 2019; 4(82): 78–81. https://doi.org/10.23670/IRJ.2019.82.4.015


Gadzhieva K.A. (Degree of incidence of human papilloma virus genotypes of oncogenous risk by the results of retrospective and prospective analysis in the city of Baku). International Research Journal 2019; 4(82): 78–81. (In Russ.). https://doi.org/10.23670/IRJ.2019.82.4.015


11. Pinheiro M., Gage J.C., Clifford G.M., Demarco M., Cheung L.C., Chen Z. et al. Association of HPV35 with cervical carcinogenesis among women of African ancestry: evidence of viral-host interaction with implications for disease intervention. Int, J, Cancer 2020; 147(10): 2677–86. DOI:10.1002/ijc.33033


12. Higgins J.P.T., Julian P.T. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, 2019. DOI:10.1002/9781119536604


13. Harrer M., Cuijpers P., Furukawa T.A., Ebert D.D. Doing Meta-Analysis with R: A Hands-On Guide. Boca Raton, FL and London: Chapman & Hall/CRC Press, 2021. https://doi.org/10.1201/9781003107347


14. Stiglic G., Watson R., Cilar L. R you ready? Using the R programme for statistical analysis and graphics. Res. Nurs. Health 2019; 42(6): 494–9. DOI: 10.1002/nur.21990


15. Annunziata C., Stellato G., Greggi S., Sanna V., Curcio M.P., Losito S. et al. Prevalence of «unclassified» HPV genotypes among women with abnormal cytology. Infectious Agents and Cancer 2018; 13(1): 26. https://doi.org/10.1186/s13027-018-0199-0


16. He L, He J. Distribution of high-risk HPV types among women in Sichuan province, China: a cross-sectional study. BMC Infect. Dis.. 2019; 19(1): 390. https://doi.org/10.1186/s12879-019-4038-8


17. Iden M., Tsaih S.W., Huang Y.W., Liu P., Xiao M., Flister M.J. et al. Multi-omics mapping of human papillomavirus integration sites illuminates novel cervical cancer target genes. Br. J. Cancer 2021; 125(10): 1408–19. DOI: 10.1038/s41416-021-01545-0


18. Fan J., Fu Y., Peng W., Li X., Shen Y., Guo E. et al. Multi-omics characterization of silent and productive HPV integration in cervical cancer. Cell Genom. 2023; 3(1):100211. DOI: 10.1016/j.xgen.2022.100211


19. Tjalma W.A.A., Depuydt C.E. Cervical cancer screening: which HPV test should be used–L1 or E6/E7? Eur. J. Obst. Gynecol. Reprod. Biol. 2013; 170(1): 45–6. DOI: 10.1016/j.ejogrb.2013.06.027


20. Аль-Яхири О.В., Аль-Яхири А.К., Беляковский В.Н., Воропаев Е.В. Типоспецифические особенности папилломавирусной инфекции у здоровых женщин и пациенток с патологией шейки матки. Проблемы здоровья и экологии. 2008; (3): 129–33. https://doi.org/10.51523/2708-6011.2008-5-3-26


Al-Yakhiri O. V., Al-Yakhiri A. K., Beliakovski V. N., Voropaev E.V. A type is specificity the feature of papillomavirus infection for healthy women and patients with pathology of cervical uterus. Health and Ecology Issues 2008; (3): 129–33. (In Russ.). https://doi.org/10.51523/2708-6011.2008-5-3-26


21. Xiao M., Xu Q., Li H., Gao H., Bie Y., Zhang Z. et al. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China. Medicine (Baltimore) 2016; 95(3): e2555. DOI: 10.1097/MD.0000000000002555


22. Hooi D.J., Lissenberg-Witte B.I., Maurits N., de Koning C., Pinedo C., Kenterv G. et al. High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine. Sex Transm. Infect. 2018; 94(4): 263–7. DOI: 10.1136/sextrans-2017-053109


23. Asato T., Maehama T., Nagai Y., Kanazawa K., Uezato H., Kariya K. A Large Case-Control Study of Cervical Cancer Risk Associated with Human Papillomavirus Infection in Japan, by Nucleotide Sequencing – Based Genotyping. J. Infect. Dis. 2004; 189(10): 1829–32. DOI: 10.1086/382896


24. Zuna R.E., Allen R.A., Moore W.E., Lu Y., Mattu R., Dunn S.T. Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type. Modern Pathology 2007; 20: 167–74. DOI: 10.1038/modpathol.3800723


25. Siegler E., Shiner M., Segev Y., Mackuli L., Lahat N., Lavie O. Prevalence and Genotype Distribution of HPV Types in Women at Risk for Cervical Neoplasia in Israel. IMAJ 2017; 19(10): 635–9. PMID: 29103242


26. do Desterro Soares Brandão Nascimento M., Castello Branco Vidal F., Custódio Neto da Silva M.A., Batista J.E., do Carmo Lacerda Barbosa M., Edson Muniz Filho W. et al. Prevalence of human papillomavirus infection among women from quilombo communities in northeastern Brazil. BMC Women’s Health 2018; 18(1). DOI: 10.1186/s12905-017-0499-3


27. Castellsagué X., Menéndez C., Loscertales M.-P., Kornegay J.R., Santos D.F., Gómez-Olivé F.X. et al. Human papillomavirus genotypes in rural Mozambique. The Lancet 2001; 358(9291): 1429–30. DOI: 10.1016/S0140-6736(01)06523-0


28. Castellsagué X., Klaustermeier J.E., Carrilho C., Albero G., Sacarlal J., Quint W. et al. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: Burden and potential for prevention. Int. J. Cancer, 2008; (122), 1901–4. DOI: 10.1002/ijc.23292


29. Halec G., Schmitt M., Dondog B., Sharkhuu E., Wentzensen N., Gheit T. et al. Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int. J. Cancer 2013; (132): 63–71. DOI: 10.1002/ijc.27605


30. Lau Y.M., Cheung T.H., Yeo W., Mo F., Yu M.Y., Lee K.M. et al. Prognostic Implication of Human Papillomavirus Types and Species in Cervical Cancer Patients Undergoing Primary Treatment. PLoS ONE 2015; 10(4). DOI:10.1371/journal.pone.0122557


31. Sakamoto J., Kamiura S., Okayama K., Okodo M., Shibata T., Osaka Y. et al. Single type infection of human papillomavirus as a cause for high-grade cervical intraepithelial neoplasia and invasive cancer in Japan. Papillomavirus Res. 2018; (6): 46–51. DOI: 10.1016/j.pvr.2018.10.001


32. Sakamoto J., Saito M., Zhang S., Takakura M., Takagi H., Sasagawa T. Determination of human papillomavirus type in archival tissue specimens of invasive cervical cancer using molecular mapping and E6/E7-based polymerase chain reaction. PLoS ONE 2022; 17(4): e0265996. DOI: 10.1371/journal.pone.0265996


33. Ciotti M., Paba P., Bonifacio D., Bonito L.D., Benedetto A., Favalli C. Single or multiple HPV types in cervical cancer and associated metastases. Oncol. Rep. 2006; (15): 143–8. https://doi.org/10.3892/or.15.1.143


34. Geraets D., Alemany L., Guimera N., Sanjose d.S., Koning M., Molijn A. et al. Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. J. Pathol. 2012; 228: 534–43. DOI: 10.1002/path.4065


35. Munger K., Werness B.A., Dyson N., Phelps W.C., Harlow E., Howley P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J, 1989; (8): 4099-4105. DOI: 10.1002/j.1460-2075.1989.tb08594.x


36. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; (63): 1129–36. DOI: 10.1016/0092-8674(90)90409-8


37. Halec G., Alemany L., Lloveras B., Schmitt M., Alejo M., Bosch F.X. et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J. Pathol, 2014; (234): 441–51. DOI: 10.1002/path.4405


38. Katz R. Biomarkers and Surrogate Markers: An FDA Perspective. NeuroRx. 2004; 1(2): 189–95. DOI: 10.1602/neurorx.1.2.189


39. Nakagawa S., Yoshikawa H., Yasugi T., Kimura M., Kawana K., Matsumoto K. et al. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J. Med. Virol. 2000; 62(2): 251–8. DOI: 10.1002/1096-9071(200010)62:2<251::aid-jmv18>3.0.co;2-v


40. Shing J.Z., Hu S., Herrero R., Hildesheim A., Porras C., Sampson J.N. et al. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. Lancet Oncol. 2022; 23(7): 940–9. DOI: 10.1016/S1470-2045(22)00291-1


About the Autors

Nadezhda А. Vinogradova, Junior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance of Consumer Rights Protection and Human Well-Being, Moscow, Russia; klimova@cmd.su; http://orcid.org/0000-0003-3288-0244
Elvira A. Domonova, Cand. Boil. Sci., Head, Scientific Group for the Development of New Methods for Diagnosis of Opportunistic and Human Papillomavirus Infections, Russian Federal Service for Surveillance of Consumer Rights Protection and Human Well-Being, Moscow, Russia; еlvira.domonova@pcr.ms; http://orcid.org/0000-0001-8262-3938
Michail A. Vinokurov, Junior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance of Consumer Rights Protection and Human Well-Being, Moscow, Russia; vinokurov@cmd.su; https://orcid.org/0000-0002-4101-0702
Anna A. Popova, Cand. Med. Sci., Senior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance of Consumer Rights Protection and Human Well-Being, Moscow, Russia; asya-med@mail.ru; https://orcid.org/0000-0001-9484-5917


Similar Articles

Back to Content

Бионика Медиа